## Contents of Shipment from Walgreens Perrysburg DC:

Boxes 1-4 contain vendor receipts from 2/1/11 through 12/31/12.
Box 5 continues with vendor receipts for 2013 and then also contains:

- Paper report for C3-C5 receipts listed by date.

1 CD enclosed that contains:

- List of C2 recipients of controlled drugs
- List of C3-C5 recipients of controlled drugs
- List 1 chemical inventory as of 02/05/13
- C2 ending inventory as of 2/05/13
- C3-C5 ending inventory as of 2/05/13
- Perrysburg couriers list
- Perrysburg DEA Fax template for Suspicious Drugs
- Perrysburg PSE receipts


## Memorandum

To: Todd Polarolo<br>From: Justin Joseph<br>Date: 5/27/2006

Re: DEA Audit Preliminary Response 03-06-06

## Accountability:

Store \#05828 never filed a chaim for WIC 675756. which was stolen from the courier. We filed a DEA Form 106. and the control drug "shipments by item" indicates product was shipped: therefore, the store was billed for controlled drugs they did not receive. The DEA checked 8 WICs total, and the remaining 7 were correct. They noted that we were very accurate in following items through the DC .

## Security:

Current cage does not meet requirements and there were no recommendations due to upcoming construction for CII. They praised our alarm and camera system and were highly complementary of our card access program. Acknowledged Tonia by name on her effectiveness

### 1301.74(b):

DEA feels that the suspicious ordering report is inadequate: they specifically did not like the DEA Factor and would like to know how we determine it. They would like a better description of the formula used to determine a suspicious order. The explanation of the formula is: All stores are put into groups of 25 based on the amount of daily prescriptions filled. The average is then taken from the orders to the DC on each group of 25 . The result is Average order * DEA factor = trigger. They said the formula should be based on (Size, pattern. frequency).
1301.74(e)

Said we should not be identifying control totes by the Red Seal. Currently we only use Red Seals for totes containing controlled substances.
$1304.04(\mathrm{a})$
Since we do not have the original POs in-house, we should have filed for central record keeping.

### 1304.11(a)

We provided them with three inventories: initial, 1 year, and biennial. The biennial was the only one to indicate that it was taken at the close of business. This should be included in the CM- 15 manual.

### 1304.22(b)

They felt that report repb309 was inadequate to use as a primary receiving record. They indicated that report repb263 was a more accurate report to use for that document as it most closely resembled a PO .

> "PRESCRIPTION FOR SUCCESS"

However they did indicate it lacked some information and did note that some of the DEA numbers were incorrect or old.
$1309.71(8)$
When we provided them with the list of PSE list one items, they asked how many were just List One. We could not give them only List One items, we need to be able to query PSE List One and Non-PSE List One items. In addition they found one WIC 664464 PSEUDOEPHEDRINE 30MG TAB (RUG) +24 was not listed as "PSE LIST ONE" under the special product type. Jill Nailor is carrently working with the Item/Vendor team on the marketing side.
$1310.03(1)$
They asked how we determine when a regulated transaction has been met. We could not provide them with a report listing regulated transactions. This should be based on the item and the milligrams of Pseudoephedrine that it contains. Who sets the threshold for regulated transactions, how is this determined? We are required to know this at the DC level.
$1310.05(\mathrm{a})(1)$
1310.05 (b)

This is similar to the response to $\mathbf{1 3 0 1 . 7 4 ( b ) , ~ b u t ~ t h e ~ f o r m u l a ~ c a n ' t ~ b e ~ b a s e d ~ o n ~ p r e s c r i p t i o n s ~ b e c a u s e ~ t h e ~}$ product is sold over the counter. They also stated that we are required to call in suspicious orders within 24 hours and should follow up with a written report within 15 days. We should not use averages due to spikes in orders during cold, flu, and allergy season. They also said that analysis is required we should not rely soley on a report.
$1310.06(\mathrm{a})(3)$
The Milligram should be listed for every transaction on report sbpb657 "special product type- shipped item report" and AHPB021 "Received Item by Product Category" report.

## Closing notes:

We are doing a great job in the DC of distributing Control and PSE List One but should have a better working knowledge on processes that happen outside of the DC. We should not have to rely on corporate to provide all of the answers.

They are going to recommend a Letter of Admonition (LOA), as it was our first DEA audit. We will have 30 days to respond to the letter. If our response mects their requirements, we will not hear back from them. They also stated that we can call them for their input prior to making any changes.

We were informed that at our next audit they will be reviewing the list of items from the letter of admonition. If we are found to be non-compliant, civil fines average $\$ 10,000$ per transaction.

They also stated they can review other DC's audits to determine if there have been ongoing issues with the same regulations. Fines could be issued to all DC's.

They thanked us for our cooperation and hospitality.
U. S. Department of Justice

Drug Enforcement Administration
431 Howard Street
Detroit, Michigan 48226
(313) 234-4000

Mr. Todd Polarolo
Distribution Center Manager
Walgreen Company
28727 Oregon Road
Perrysburg, Ohio 43551
Dear Mr. Polarolo:
During the month of March 2006, Diversion Investigators (DI) Angela Francis and James Rafalski of the Drug Enforcement Administration (DEA) completed a regulatory investigation of your firm. This regulatory investigation revealed recordkeeping inadequacies and security deficiencies. The discrepancies noted are as follows:

1) The formulation utilized by the firm for reporting suspicious ordering of controlled substances was insufficient. The system set its standard of deviation from a normal ordering pattern in groupings of 25 customers, based on the number of non-controlled and controlled substance prescriptions filled by each customer. The system in place determined the amount of daily prescriptions filled by each of its customers of both non-controlled and controlled substance prescriptions. This amount was utilized to place each customer in groupings each containing 25 customers. Of these 25 customer groupings, the firm calculated the average order per item of each controlled substance. The firm then took the average and multiplied that figure by three. This calculated figure was then used as the base to report suspicious orders above such figure.

Section 1301.74(b) of Title 21 of the Code of Federal Regulations (CFR) requires the registrant design and operate a system to disclose to the registrant, suspicious orders of controlled substances, and inform DEA of suspicious orders.
2) The firm utilized shipping containers through contract carriers that indicated the tote contents were controlled substances. The firm utilized a numbered tote tag that was red in color solely on totes containing controlled substances.

Section 1301.74(e) of Title 21 of the CFR requires the registrant is responsible to employ precautions, to guard against storage or in-transmit losses. Such precautions include that shipping containers do not indicate that contents are controlled substances.
3) The firm failed to submit written notification to DEA for central recordkeeping. The original purchase records were not maintained at the registered location. The
purchasing of controlled substances is performed at Walgreen Company Corporate Headquarters in Deerfield, Illinois. Original purchase records are maintained at the Walgreen Company facility in Deerfield, Illinois.

Section 1304.04(a) of Title 21 of the CFR requires the registrant notify and submit, in written format, their intent for central recordkeeping to DEA.
4) The biennial inventory and the inventory produced for the accountability audit failed to indicate if it was taken at the opening or close of business.

Section 1304.11(a) of Title 21 of the CFR requires the registrant indicate on the required inventories if it was taken at the opening of business or close of business.
5) The firm inaccurately recorded a loss in transit as a distribution which resulted in an accountability error in the Hydrocodone, 10 mg product audited.

Section 1304.21 (d) of Title 21 of the CFR requires the registrant record the date of distribution on the date controlled substances are actually distributed.
6) The firm's maintenance of purchase records was inadequate. The primary purchase record provided to DIs Francis and Rafalski was Walgreen Company Report Number REPB309. The report was a computer printout listing receipts solely by specific item number. The report failed to contain numerous required items. The REPB309 failed to contain the name, address and registration number of the vendor where the controlled substances were acquired. Additionally, incorrect DEA registration numbers were recorded on the purchase record. The primary purchase record should record the receipt as indicated on original purchase records, which are maintained at the corporate facility in Deerfield, Illinois. Since the original purchase records are not maintained at the registered location, central recordkeeping should be considered.

Section 1304.22(b) of Title 21 of the CFR requires the registrant maintain records with specific information. The information must include name of substance, each finished form, number of units acquired, date of acquisition, name, address and registration number of the person from whom the units were acquired.
7) The firm failed to ascertain which List I chemicals were handled at the registered location. Walgreen Company was advised their List I chemical products should have been identified as "PSE List I." The firm failed to identify all List I chemical products as "PSE List I."

Section 1309.71(8) of Title 21 of the CFR states that, in evaluating the effectiveness of security controls and procedures, DEA shall consider the registrant maintain a system for monitoring the receipt, distribution and disposition of List I chemicals in its operations.
8) The firm does not have knowledge of thresholds for List I chemicals. The firm was unable to determine if a system was in place to establish if the thresholds had been met for a regulated transaction.

Section 1310.03(f) of Title 21 of the CFR states the listed chemicals for which thresholds have been established and the quantitative threshold utilized, to determine whether a receipt or sale is a regulated transaction.
9) The firm does not accurately identify all List I chemicals handled by their facility. This failure to maintain the identity of List I chemicals resulted in the firm's inability to maintain a system for suspicious ordering of List I chemicals.

Sections 1310.05 (a)(1) and $1310.05(\mathrm{~b})$ of Title 21 of the CFR states each regulated person shall report to DEA List I chemical transactions of extraordinary quantity, uncommon method of payment or delivery, or any other circumstances, that is indicative of possible List I chemical violations. It further states that the reports are to be made orally to the Drug Enforcement Administration and written reports of such transactions shall be filed within 15 days after the regulated person becomes aware of the transaction.
10) The firm did not record the milligram amount of the List I chemical products on any of the records reviewed by investigators.

Section $1310.06(a)(3)$ of Title 21 of the CFR states that each required record shall include the quantity and form of packaging of the List I chemical.

This letter is formal notification that your failure to maintain adequate records and security for controlled substances and List I chemicals constitutes violations of the Controlled Substances Act. At this time, you are being afforded the opportunity to comply with the requirements of the Controlled Substances Act which were outlined by DIs Francis and Rafalski with the management of your firm in March, 2006.

Please advise this office in writing within thirty (30) days of the action taken or planned to correct these violations.

If you have any questions concerning this matter, please contact Acting Group Supervisor Barbara K. Dobric at 313-234-4000.


## This is a signed confirmation that we received these documents from the DEA.



| DEA USE ONLY |
| :--- |
| FILE NUMBER |



## STATEMENT OF RIGHTS

1. You have a constitutional right not to have an administrative inspection made without an administrative inspection warrant.
2. You have the right to refuse to consent to this inspection.
3. Anything of an incriminating nature which may be found may be seized and used against you in a criminal prosecution.
4. You shall be presented with a copy of this Notice of Inspection.
5. You may withdraw your consent at any time during the course of the inspection.

## ACKNOWLEDGMENT AND CONSENT


by DEA
D/I Angela R. Francis , who (Title and Name)
has identified himselfherself to me with his/her credentials and presented me with this Notice of inspection containing a copy of sections 302 (f) and 510 (a). (b) and (c) of the Controlled Substances Act ( 21 U.S.C. 822 (f) and 21 U.S.C. 880 (a), (b) and (c), printed hereon, * authorizing an inspection of the above-described controlled premises. I hereby acknowledge receipt of this Notice of Inspection. In addition, I hereby certify that I am the
(President) (Manager) (Owner)
for the premises described in this Notice of Inspection; that I have read the foregoing and understand its contents; that I have authority to act in this matter and have signed this Notice of Inspection pursuant to my authority.

I understand what my rights are concerning inspection. No threats or promises have been made to me and no pressure of any kind has been used against me. I voluntarily give consent for inspection of these controlied premises.


## * These sections are quoted below.

SEC. 302.(f) The Attorney General is authorized to inspect the establishment of a registrant or applicant in accordance with the rules and regulations promulgated by him.

SEC. 510.(a) As used in this section, the term "controlled premises" means -
(1) places where original or other records or documents required under this title are kept or required to be kept, and
(2) places, including factories, warehouses, or other establishments, and conveyances, where persons registered under section 303 (or exempted from registration under section 302 (d)) may lawfully hold, manufacture, or distribute, dispense, administer, or otherwise dispose of controlled substances.
(b)(1) For the purpose of inspecting, copying, and verifying the correctness of records, reports, or other documents required to be kept or made under this title and otherwise facilitating the carrying out of his functions under this title, the Attorney General is authorized, in accordance with this section, to enter controlled premises and to conduct administrative inspections thereof, and of the things specified in this section, relevant to those functions.
(2) Such entries and inspections shall be carried out through officers or employees (hereinafter referred to as "inspectors") designated by the Attorney General. Any such inspector, upon stating his purpose and presenting to the owner, operator, or agent in charge of such premises (A) appropriate credentials and (B) a written notice of his inspection authority (which notice in the case of an inspection requiring, or in fact supported by, an administrative inspection warrant shall consist of such warrant), shall have the right to enter such premises and conduct such inspection at reasonable times.
(3) Except as may otherwise be indicated in an applicable inspection warrant, the inspector shall have the right -
(A) to inspect and copy records, reports, and other documents required to be kept or made under this title;
(B) to inspect, within reasonable limits and in a reasonable manner, controlled premises and all pertinent equipment, finished and unfinished drugs and other substances or materials, containers, and labeling found therein, and, except as provided in paragraph (5) of this subsection, all other things therein (including records, files, papers, processes, controls, and facilities) appropriate for verification of the records, reports, and documents referred to in clause (A) or otherwise bearing on the provisions of this title; and
(C) to inventory any stock of any controlled substance therein and obtain samples of any such substance. (4) Except when the owner, operator, or agent in charge of the controlled
(4) Except when the owner, operator, or agent in charge of the controlled premises so consents in writing, no inspection authorized by this section shall extend to -
(A) financial data;
(B) sales data other than shipment data; or
(C) pricing data.
(c) A warrant under this section shall not be required for the inspection of books and records pursuant to an administrative subpena issued in accordance with section 506, nor for entries and administrative inspections (including seizures of property) -
(1) with the consent of the owner, operator, or agent in charge of the controlled premises;
(2) in situations presenting imminent danger to health or safety;
(3) in situations involving inspection of conveyances where there is reasonable cause to believe that the mobility of the conveyance makes it impracticable to obtain a warrant;
(4) in any other exceptional or emergency circumstances where time or opportunity to apply for a warrant is lacking; or
(5) in any other situations where a warrant is not constitutionally required.

CLOSING INVENTORY
NAME OF FIRM Walgreen (o, Date $\frac{2 / 27 / 06}{43551}$
ADDRESS 28727 Oregon Road, Terrysburg, ohio
DEA NO.
$\qquad$
 I certify that this inventory is accurate and include all of the above controlled substances in stock.


## Board of Directors

As of Nowember 14, 2005

## Directors

## David W. Bernauer

Chairman and Chief Executive Officer Elected 1999

## Jeffrey A. Rein

President and Chief Operating Officer Elected 2003

## William C. Foote

Chairman of the Board,
Chief Executive Officer and President
USG Corporation
Elected 1997 (1) (4*)
James J. Howard
Chairman Emeritus
Xcel Energy, inc.
Elected 1986 (2) (4)

## Alan G. McNally

Chairman
Harris Financial Corporation
Elected 1999 (3) (4)

## Cordell Reed

Former Senior Vice President
Commonweath Edison Co.
Elected $1994\left(2^{*}\right)(3)$

## David Y. Schwartz

Former Patner
Arthur Andersen LLP
Elected 2000 (1) ( $3^{*}$ )
John B. Schwemm
Former Chairman and Chiet Executive Officer R.R. Donnelley \& Sons Co.

Elected $1985(1 *)(2)(4)$
James A. Skinner
Vice Chairman and
Chief Executive Officer
McDonald's Corporation
Elected 2005
Marilou M. von Ferstel
Former Executive Vice President
and General Manager
Ogily Adams \& Rinehart
Elected 1987 (1) (4)
Charles R. Walgreen III
Chairman Emeritus
Elected 1963 (3)
(1) Audit Committee
(2) Compensation Committee
(3) Finance Committee
(4) Nominating and Governance Committee

* Committer Chair


## Officers

As of Nouenber 14, 2005

## Corporate Officers

## Chairman

David W. Bemauer
Chief Executive Officer

## President

Jeffrey A. Rein
Chief Operating Officer
Exacutive Vice Presidents
Jerome B. Karlin
Store Operations
Trent E. Taylor
Chief information Officer
Gregory D. Wasson
President
Walgreens Health Services
Senior Vice Presidents
R. Bruce Bryant

Western Store Operations
George C. Elers
Southem Store Operations
John W. Gleeson
Corporate Strategy
and Treasurer
Dana I. Green
General Connsel and
Corporate Secretary
J. Ranoloiph Lewis

Distribution \& Logistics
Barry L. Mark
Midwest Slore Operations
George J. Riedl
Marketing
William M. Rudolphsen
Chief Financial Officer
William A. Shiel
Facilites Development
Mark A. Wagner Eastern Store Operations

Vice Presidents
Kermit R. Crawtord Executive Vice President
PBM Services
Robert M. Kral
Purchasing
Kenneth R. Weigand
Human Resources

## Operational Vice Presidents

## Store Operations

C. Mark Ashworth

Pault. Bonk
Kenneth B. Corin
Lisa D. Enlers
George C. Eilers Jr.
Debra M. Ferguson
John J. Foley
David L. Gloudemans
John W. Grant
W. Thomas Grayson

Frank C. Grill
Wiliam M. Handal
Patrick E. Hanifen
William J. Hose
Marin W. Hutchens
David R. Lovejoy
Nivia L. Santiago
John W. Spina
Roberto M. Valencia
Kevin P. Walgreen
Stewart B. Wasson
Christine D. Whetan
Barry W. Zins

## Pharmacy Services

Donald C. Huonker
Walgreens Health Services
Michael D. Tovian
Managed Care Sales

## Controller

Mia M. Scholz
Chief Accounting Officer
General Auditor
Chester G. Young

## U.S. DEPARTMENT OF JUSTICE - ORUG ENFORCEMENT ADMINISTRATION <br> RECEIPT FOR CASH OR OTHER ITEMS



RECEIPT FOR CASH OR OTHER ITEMS


I hereby acknowledge receipt of the following described cash or other items), which was given into my custody by the above named individual.


GOAMFDEA-12 (9-00) Previous editions obsolete
Electronic Form Version Designed in deform 5.2 Version

July 27, 2006

## VIA FACSIMILE (313) 234-4149

And First Class Mail
Barbara K. Dobric
Drug Enforcement Administration
431 Howard Street
Detroit, Michigan 48226

## Re: Walgreens Distribution Center

Perrysburg, Ohio
Dear Ms. Dobric:
In furtherance of our recent telephone conversations, please accept the following responses to the issues identified during the March 2006 regulatory investigation of the above referenced facility.

Walgreen Co. ("Walgreens") strives to maintain our distribution operations at the highest level of compliance and we appreciate the observations of the Drug Enforcement Administration ("DEA") investigators that serve to supplement our own internal control systems. The responses below to the issues identified during the inspection should not be considered as either an admission or denial of any alleged violation but instead as assurances to DEA that each of these matters has been satisfactorily addressed.

## 1. Controlled Substance Suspicious Orders

Walgreens is currently pursuing the necessary programming to modify this formula in accordance with the voluntary formula listed in Appendix E-3 of the DEA Chemical Handler's Manual. Walgreens expects that these programming changes will be completed and implemented within the next six (6) months.

## 2. Shipping Containers

Walgreens has modified the tote tags used on shipping containers for controlled substances so that they are now indistinguishable from the shipping containers used for non-controlled substances.

## 3. Central Recordkeeping

Walgreens maintains that 21 CFR $\S 1304.04$ (a) does not require DEA registrants to maintain copies of purchase orders at the registered facility. By letter dated June 26, 2006, Walgreens notified DEA of its intent to maintain controlled substance purchase order and invoice information for this facility centrally at the corporate headquarters. A copy of this notification is enclosed for your records.

## 4. Inventories

Enclosed is a copy of the most recent biennial inventory taken on December 30, 2005, which indicates that the same was taken at the close of business. Personnel at the

Perrysburg facility have reviewed other inventories that are maintained and have corrected these to more clearly indicate that each was taken at the open or close of business.

## 5. Reporting Losses in Transit

The loss in transit identified during the investigation was properly reported on DEA form 106. Programming changes were implemented as of July 15, 2006, which will ensure that any future loss in transit is not recorded as a distribution.

## 6. Primary Purchase Record

Walgreens has identified report REPB309 as the primary receiving record for this facility. Enclosed is a sample copy for your review. The REPB309 includes each of the elements specified in 21 CFR $\$ 1304.22$ (b). In the alternative, report REPB307 is available on site and can also be used as a receiving record. A sample of this report is also enclosed. Walgreens would appreciate if you could confirm that the REPB309, and/or the REPB307 fully comply with DEA regulations.

## 7. List I Chemical Identification

In conjunction with the implementation of the requirements under the "Combat Methamphetamine Epidemic Act of 2005", Walgreens is conducting a review of all products containing pseudoephedrine or ephedrine. Walgreens expects to discontinue the sale and distributon of many of these products. Additionally, a considerable number of products are being reformulated by the respective manufacturers; replacing pseudoephedrine with another decongestant. A new listing of products containing pseudoephedrine entitled "PSE List I" will be available on or before July 31, 2006.

## 8. List I Chemical Thresholds

Walgreens' distribution of all List I chemicals is limited solely to the distribution between the applicable distribution center and the Company's individual stores. Arguably, any such distribution is excluded from the definition of a regulated transaction, pursuant to 21 CFR § 1300.02(b)(28), because each distribution is a lawful intra-company transaction completed in the usual course of business. Notwithstanding that all such distributions are intra-company, proper recordkeeping is maintained in accordance with 21 CFR 1310, with each and every unit being accounted for between the distribution center and the respective store. Walgreens timely submits its monthly "suspicious order" report in accordance with 21 CFR § 1301.74(b), and additionally, has implemented specific line item order limits/restrictions for various products which contain List I chemicals.

## 9. List I Chemical Suspicious Orders

As reflected in the responses to paragraphs 7 and 8 above, Walgreens is preparing an updated listing entitled "PSE List I." However, as also explained above, all of the Company's transactions from it's distribution centers are intra-company transactions, where, under no circumstance, especially in light of the aforementioned item line limits, could there be a regulated transaction, which could arguably be classified as a "suspicious order", involving '"...an extraordinary quantity of listed chemical, an uncommon method of payment or delivery, or any other circumstance that the regulated

Walgreens - Perrysburg Distribution Center
DEA Response Material, 6/5/2006

The materials enclosed are copies of what the DEA was shown. Point by point:

1. Formulary for suspicious controlled drug orders

- The Formulary is spelled out under each individual WIC on the right side of the page.

2. Controlled tote identification

- No documentation on the DC end.

3. Central Record-Keeping

- No documentation on the DC end.

4. Biennial Inventory

- As you can see on the enclosed cover sheet, it clearly states that the biennial inventory was performed at the close of business. We did not previously make an indication on the weekly inventories, but as you can see we have now added it to our weekly inventories as well.

5. Inaccurately documented a loss-in-transit as a sale

- No documentation redquested from the DC

6. Receiving Report

- This is the 309 , indicated in the CM-15 as being our primary receiving record.


## 7-10. List One

- Corporate to call DEA for clarification on these items.


## 1. Suspicious Controlled Drug Order Report

WALGREEN COMPANY
SUSPICIOUS DRUG ORDERS FOR OTC PRODUCT 28727 OREGON RD WAREHOUSE MII
WAREHOUSE DEA RWE294493

05549

END OF REPORT CDGあagII


## 4. Biennial, Weekly Inventory Cover Sheets

$\qquad$ State: Ohio Zip Code: 43551

DEA Registration No. RW0294493 Date of Inventory: December 30, 2004.

Inventory Taken at Close of Business


NOTE:

1. DO NOT SEND YOUR COMPLETED INVENTORY TO DEA OR PHARMACY BOARD. ONE COPY SHOULD BE RETAINED AT THE LOCATION APPEARING ON THE REGISTRATION CERTIFICATION FOR FIVE YEARS.
2. SEND A SECOND COPY OF THIS INVENTORY TO LOGISTICS.

Intracompany Correspondence
Date: May 24, 2006: Close of Business

Subject: A.R.C.O.S. and Controlled Drug Weekly Inventory
From: Mona Thorstenson
To: Justin Joseph

There were no variances found during the weekly A.R.C.O.S. and control drug inventory for the above date.

## 6. REPB309 - Controlled Item Receipt Detail

$\begin{array}{lr}\text { Date...: } & 2 / 27106 \\ \text { Time...: } & 13: 22: 27 \\ \text { Page...: } & 1\end{array}$





[^0]$\begin{array}{ll}\text { REPORT PERIOD } \\ \text { ITEM } & 2 / 23 / 05 \\ 675756 & 2 / 27 / 06 \\ \text { DESCRIPTION }\end{array}$ 675756 DESCRIPTION
ARCOS Drugs


 WA LGREENS
CONTROLLED ITEM RECEIPTS - DETAIL



HYDROCOD-APAP $10-500 \mathrm{~TB} \quad(\mathrm{WT})+500$

$\stackrel{\ddot{c}}{6}$


## Report Number: REPB309 <br> Report Number: REPB309 Requested By. : AGALLAFERD

REPORT PERIOD . : $2 / 23 / 05-2 / 27 / 06$ $2 / 23 / 05-2 / 27 / 06$
675756 DESCRIPTION
ARCOS Drugs
ARCOS Drugs
091170
WATSON "C"
605 TRI-STATE PARKWAY

号号
REPORT PERIOD
ITEM
CATEGORY . .
VENDOR
VENDOR NAME
VEND SHIP POINT
DEA NUMber
DATE
APPROVED $7 / 21 / 05$
$8 / 12 / 05$
$8 / 19 / 05$ 9/09/05

 $\begin{array}{ll}n & n \\ 0 & 0 \\ 0 & 4 \\ 0 & - \\ 0 & 0 \\ 0 & 1\end{array}$ | $n$ | $\stackrel{n}{0}$ |
| :--- | :--- | $\begin{array}{ll}n & n \\ - & 0 \\ - & 0 \\ \underset{-1}{-} & 7\end{array}$

 12/15/05 $\stackrel{\sim}{\circ}$ 1/12/06
 $\stackrel{\circ}{\stackrel{\circ}{6}}$ $2 / 09 / 06$
$2 / 26 / 06$
$2 / 24 / 06$ DEA Number
DATE RECEIVED $7 / 20 / 05$
$8 / 11 / 05$ 8/18/05 9/08/05 2/16/05 9/30/05 10/14/05 10/26/05 11/11/05 12/29/05 12/09/05 12/14/05 12/22/05 $\stackrel{\otimes}{\stackrel{\circ}{-}}$ $1 / 19 / 06$
$1 / 25 / 06$ $1 / 25 / 06$
$2 / 06 / 06$ $2 / 08 / 06$
$2 / 15 / 06$
**** End fof Report



$$
\begin{aligned}
& \text { Report Number: } \\
& \text { Requested } \mathrm{By}: \mathrm{A}
\end{aligned}
$$

$$
\begin{aligned}
& 062224 \\
& \hline \mathrm{PFIzER} \text { "C" }
\end{aligned}
$$

$$
5-\frac{2 / 27 / 06}{\text { DESCRIPTION }}
$$

WALGREENS

$$
\begin{aligned}
& \begin{array}{c}
\text { PURCHASE } \\
\text { ORDER }
\end{array} \\
& 11014320 \\
& 11035689 \\
& 11400855 \\
& 11402299 \\
& 11405066 \\
& 11019305 \\
& 11413206 \\
& 11415917 \\
& 11418362 \\
& 11421393 \\
& 11422742 \\
& 11425459 \\
& 11427000 \\
& 11429507 \\
& 11432108 \\
& 11437815 \\
& 11435880 \\
& 11440830 \\
& 11442076 \\
& 11444730 \\
& 11448722 \\
& 11452593
\end{aligned}
$$

Report Number: REPB309
Requested By, : AGALLAHERD
号量


|  | STATE：ZIP： | 89511 |
| :---: | :---: | :---: |
| PURCHASE |  |  |
| ORDER | FREIGHT BILL | CARR |
| 11454189 | 072205－716164A | FEDX |
| 13456958 | 072905－716164A | EDX |
| 11459460 | 080405－716164 | FEDX |
| 11461815 | 081205－716164A | FEDX |
| 11462779 | 081705－716264 | FEDX |
| 11464053 | 081905－641164A | fedx |
| 11466639 | 083005－716164A | EDX |
| 11469113 | 090205－726164B | FEDX |
| 11472503 | 091505－716165 | PEDX |
| 11471408 | 090905－716164B | FEDX |
| 11476670 | 092305－716165AB | FEDX |
| 11477840 | 092905－726165 | pedx |
| 11480347 | 100605－716165 | FEDX |
| 21483208 | 101305－716265A | $x$ |
| 11484516 | 101405－716165A | PEDX |
| 11487045 | 102105－716165A | FEDX |
| 11489472 | 103105－716165C | FEDX |
| 11491869 | 110405－716165C | FEDX |
| 31492986 | 111005－716165AA | FEDX |
| 21497162 | 111805－716166C | FEDX |
| 11498689 | 112305－716166 | FEDX |
| 11502683 | 120205－716166A | Fe |

[^1]$\begin{array}{lr}\text { Date...: } & 2 / 27106 \\ \text { Time...: } & 13: 22: 42 \\ \text { Page...: } & 3\end{array}$
$\begin{array}{ll}\text { STATE: } & \text { 2IP: } \\ & \text { 89517 } \\ \text { FREIGHT BILL } & \text { CARR } \\ \text { 120905-716166AA } & \text { FEDX } \\ \text { 121605-716166AA } & \text { FEDX } \\ 122305-716166 A & \text { FEDX } \\ 010406-716166 & \text { FEDX } \\ 011106-716166 A & \text { FEDX } \\ 011306-705166 B & \text { FEDX } \\ 012006-716166 D & \text { FEDX } \\ 012706-716166 A & \text { FEDX } \\ 020306-716167 A A & \text { FEDX } \\ 021606-716166 & \text { FEDX } \\ 021706-716166 & \text { FEDX }\end{array}$
$\begin{gathered}\text { PURCRASE } \\ \text { ORDR }\end{gathered}$
11505379
11507782
11509335
11510626
11515882
11517375
11519730
11522293
11524629
11528448
11529908
$001+\quad$ gui owt xunve
walgreens
Walgreens
Controlled item receipts - detail
CONTROL
CATEGORY
CTL DRUG
CTL DRUG
CTL DRUG
CTI DRUG
CTL DRUG
CTL dRUG
CTL DRUG
CTL DRUG
CTL DRUG
CTL DRUG
CTL DRUG
$\stackrel{3}{6}$

xanax img tab

1025 SANDHILL ROAD
111778240
PEF224 "C"
1025 SANDHIL


Report Number: $\mathrm{REPB3O9}$
Requested By:
AGALLAHERD



| 8240 |
| :--- | :--- |
|  |

品品
REPORT PERTOD
ITEM
CATEGORY
VENDOR
VENDOR NAME
VEND SHIP POINT
DEA Number.






ORDERED
ONLIES
48
$\$ 11778240$
REPORT PERTOD : :

DA Number
DATE
DATE
RECEIVED
12/12/05
12/20/05
22/28/05
1/05/05
1/12/06
1/19/06
1/22/06
1/30/06
2/06/06
2/16/06
**** End of Report ****




CONTROLLED ITEM RECEIPTS - DETAIL
WALGREENS

$\begin{array}{cl} & \text { CITY: } \\ & \\ \text { RCVD } & \text { CONTROL } \\ \text { ONLIES } & \text { CATEGORY } \\ 768 & \text { CTL DRUG }\end{array}$

$2 / 27 / 06$
Report Number: REPB309
Requested By. AGALLAHERD
RERORT PERIOD
ITEM.

$2 / 23 / 05$
594167
DESCRIPTIO
Drugs
032825
GRNSTONE C
IIOO00000
ADJ CASE
IND PACK
48
$2 / 23 / 05$ - $2 / 27 / 06$
594167
DESCRTPTIO
032825
GRNSTONE C
II0000000
ADJ CASE
IND PACK

48
ITEATE
VENDOR
VEAD
VENDOR NAAE
VENDOR NAME PIIT
VEND SHIP POINT
$2 / 23 / 05$ - $2 / 27 / 06$
4167
DESCRIPTIO
2825
NNSTONE C
0000000
ADJ CASE
IND PACK
48
$2 / 23 / 05$ - $2 / 27 / 06$
4167
DESCRIPTIO
2825
NNSTONE C
0000000
ADJ CASE
IND PACK
48
CONTROLLED ITEM RECEIPTS - DETAIL
$2 / 23 / 05$ - $2 / 27 / 06$
4167
DESCRIPTIO
2825
NNSTONE C
0000000
ADJ CASE
IND PACK
48
$2 / 23 / 05$
94167
DESCRIPTIO
rugs
32825
RNSTONE C
10000000
ADJ CASE
IND PACK
48
****
DATE
ARPROVED
$1 / 31 / 06$
Of Report
DATE
RECEIVED
呂
$\begin{array}{ll}\text { Date...: } & 2 / 27 / 06 \\ \text { Time....: } & 13: 23: 01 \\ \text { Page...: } & 1\end{array}$


| PURCHASE |
| :---: |
| ORDER |
| 11401526 |
| 11401526 |
| 21046 |
| 11409498 |
| 21046 |
| 11420609 |
| 21046 |
| 11426189 |
| 11436878 |
| 11447953 |
| 11453450 |
| 11463349 |
| 21046 |
| 11465895 |
| 21046 |
| 11473258 |
| 21046 |
| 11478475 |
| 11486325 |
| 21046 |
| 1193645 |
| 11496226 |
| 21046 |
| 1496226 |
| 11504535 |


 $2 / 23 / 05-\underset{2 / 27 / 06}{677997}$
DESCRIPTION Report Number: $\mathrm{REPB309}$
Requested By:
AGALLAHERD
$\begin{array}{lr}\text { Date．．．：} & 2 / 27 / 06 \\ \text { Time．．．：} & \text { 13：23：11 } \\ \text { Page．．．：} & 1\end{array}$

|  | $\begin{aligned} & \text { 答 } \end{aligned}$ | $\begin{aligned} & \mathbb{N}_{5} \\ & \mathscr{S} \end{aligned}$ | $\begin{aligned} & \tilde{F}_{5}^{2} \\ & \text { B } \end{aligned}$ | $\begin{aligned} & \text { N } \\ & \stackrel{\omega}{5} \end{aligned}$ | $\begin{aligned} & \mathscr{O} \\ & \text { E} \end{aligned}$ | $\begin{aligned} & \text { on } \\ & \text { 号 } \end{aligned}$ | $\begin{aligned} & \mathscr{甘} \\ & \tilde{S} \end{aligned}$ | $\begin{aligned} & \text { N } \\ & \text { م } \end{aligned}$ | $\begin{aligned} & \text { \% } \\ & \text { B } \end{aligned}$ | $\begin{aligned} & \text { N } \\ & \dot{5} \end{aligned}$ | $\begin{aligned} & \mathscr{5} \\ & \vdots \\ & \hline \end{aligned}$ | $\begin{aligned} & \mathscr{E} \\ & \stackrel{E}{5} \end{aligned}$ | $\frac{\mathrm{B}}{5}$ | $\begin{aligned} & \text { N } \\ & \text { n } \end{aligned}$ | $\begin{aligned} & \% \\ & \tilde{F} \\ & \hline \end{aligned}$ | $\frac{8}{2}$ | $\begin{gathered} \text { 唇 } \\ \hline \end{gathered}$ | $\stackrel{R}{a}$ | 易 | $\begin{aligned} & \text { © } \\ & \text { S } \end{aligned}$ | 品 | $\begin{gathered} \text { 曷 } \\ \stackrel{g}{\Delta} \\ \hline \end{gathered}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | $\begin{aligned} & \stackrel{0}{0} \\ & \stackrel{1}{a} \\ & \stackrel{\rightharpoonup}{\square} \end{aligned}$ | $\begin{aligned} & \text { m } \\ & \stackrel{m}{m} \\ & \stackrel{\rightharpoonup}{g} \end{aligned}$ | $\begin{aligned} & \stackrel{\rightharpoonup}{\omega} \\ & \stackrel{\rightharpoonup}{\sigma} \\ & \stackrel{\rightharpoonup}{\mathrm{g}} \end{aligned}$ |  |  | $\begin{aligned} & \ddot{d} \\ & \underset{d}{d} \\ & \underset{d}{4} \end{aligned}$ | $\begin{gathered} \stackrel{7}{9} \\ \stackrel{y}{7} \end{gathered}$ |  | $\begin{aligned} & \text { à } \\ & \stackrel{y y y y}{c} \\ & \text { My } \end{aligned}$ | $\begin{aligned} & \mathscr{d} \\ & \underset{\sim}{4} \\ & \underset{\sim}{u} \end{aligned}$ | $\begin{aligned} & \stackrel{\sim}{\underset{\sim}{\infty}} \\ & \underset{\sim}{\infty} \\ & \underset{\sim}{3} \end{aligned}$ |  | $\begin{aligned} & \text { g } \\ & \text { c } \\ & \text { y } \end{aligned}$ |  | $\begin{aligned} & \stackrel{8}{0} \\ & \stackrel{y}{6} \\ & \stackrel{y}{8} \end{aligned}$ |  |  |  | $\begin{aligned} & \text { Ñ } \\ & \stackrel{y}{\circ} \\ & \underset{\sim}{2} \end{aligned}$ |  |  |

anoot＋（IVy）ayi oot n－zajonava

$\stackrel{\ddot{3}}{\stackrel{3}{4}}$
 walgreens CONTROLLED ITEM RECEIPTS－DETAIL Report Number：REPB309
Requested By，AGALLAHERD

Date．．．： $2 / 27 / 06$
Time．．．： $13: 23: 11$
Page．．．：

|  | $\begin{aligned} & \text { 品 } \\ & \frac{y}{d} \end{aligned}$ | $\begin{aligned} & \text { N } \\ & \text { W } \\ & \text { 号 } \end{aligned}$ | $\underset{\sim}{B}$ | $\begin{aligned} & \stackrel{\Gamma}{C} \\ & \vdots \\ & \hline \end{aligned}$ | $\underset{M}{\stackrel{\theta}{G}}$ | $\underset{\mathrm{a}_{1}}{\stackrel{a}{\mathrm{G}}}$ | $\underset{A}{\stackrel{Q}{E}}$ | $\begin{aligned} & \mathscr{N} \\ & \infty \\ & B \end{aligned}$ | $\begin{aligned} & \text { 昆 } \\ & 9 \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\underset{\substack{\text { OH} \\ \text { H }}}{ }$ |  |  |  |  |  |  |  | § |  |
|  | $\underset{\infty}{\vec{H}}$ | $\underset{m}{m}$ |  | $$ | 9 |  |  | $\stackrel{\text { \％}}{\substack{3 \\ 3}}$ |  |
|  |  | $\underset{\sim}{x}$ | $\underset{\sim}{8}$ | 祭 | $\stackrel{4}{7}$ |  |  | $\underset{\substack{24 \\ i}}{ }$ | $\stackrel{0}{\mathrm{~N}}$ |
|  | 蒠 | $\stackrel{1}{8}$ | $\stackrel{5}{5}$ | $\stackrel{1}{8}$ | ¢ | $\stackrel{\square}{*}$ | $\stackrel{\text {－}}{\text {－}}$ | $\stackrel{\circ}{\circ}$ | $\mathbf{N}_{\infty}^{\infty}$ |
|  | $\stackrel{+}{4}$ | $\begin{aligned} & 8 \\ & 8 \\ & 8 \end{aligned}$ | $\stackrel{\infty}{\infty} \underset{\infty}{\infty}$ | m | $\underset{\infty}{\infty}$ | $\underset{\sim}{\infty}$ | $\stackrel{\infty}{\infty+\infty}$ | $\begin{gathered} \mathbf{\circ} \\ \mathbf{\circ} \\ \hline \end{gathered}$ | $\underset{\infty}{\infty}$ |
|  |  |  |  |  |  |  |  |  | $$ |

PURCHASE
ORDER
11503846
11506379
11508538
11515867
11518387
11520930
11525748
11528426
11531157
Report Number：REPB309
Requested By：AGALLAHERD
WA LGREENS
CONTROLLED ITEM RECEIPTS－DETAIL

anoot＋（INZ）gyd 001 N －Lavonaya

|  |  | $\begin{aligned} & \text { y } \\ & \text { O } \\ & \text { 㚗 } \end{aligned}$ | $\begin{aligned} & 9 \\ & \frac{g}{g} \\ & \frac{4}{U} \end{aligned}$ |  | $\begin{aligned} & \text { 品 } \\ & \text { 昆 } \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \end{aligned}$ |  |  | 景 | $\begin{aligned} & \text { y } \\ & \text { 品 } \\ & \text { E } \end{aligned}$ | 号 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  | $\frac{8}{4}$ | ¢ | $\stackrel{\sim}{\sim}$ | － | $\stackrel{\circ}{\square}$ | $\stackrel{\circ}{\sim}$ | 앙 |  | － | \％ | 8 |

[^2]
REPORT PERIOD ．： $2 / 23 / 0$
ITEM

$\begin{array}{lr}\text { Date．．．：} & 2 / 27 / 06 \\ \text { Time．．．：} & 13: 23: 18 \\ \text { Page．．．：} & 1\end{array}$

$\underset{\sim}{\underset{\sim}{a}}$


WALGREENS
CONTROLLED ITEM REGEIpTS－detail
Cheratussin AC SYRUP（QT）+1602
CHERATUSSIN AC SYRUP（QT）+1602


 0
品
易 0
$\frac{0}{2}$
4
8 $\begin{array}{ll}9 & 9 \\ 0 \\ 0\end{array}$ 9
0
品
曷 0
0
0 90
0
0
4

4 | 9 | 9 |
| :--- | :--- |
| 2 |  |
| 2 |  |

 9
$\frac{9}{2}$
르́ 9
品
号
 0
3
8
8
8
8

范
 $\stackrel{\infty}{\stackrel{\circ}{\circ}}$ $\stackrel{\circ}{\circ}$

 2／23／05－ $2 / 27 / 06$ Report Number：REPB309
Requested By．：AGALLAHERD REPORT PERIOD $:$
TTEM
CATEGORY
VENDOR
VENDOR NAME
VENDOR NAME
VEND SHIP POINT
DEA NUmber ．思范 RQ0110433号号

$\begin{array}{cc}\text { Date...: } & 2 / 27 / 05 \\ \text { Time...: } & 13: 23: 18 \\ \text { Page...: } & 2\end{array}$

|  | STATE: ZIP; |  |
| :--- | :--- | :--- |
| PURCHASE <br> ORDER | FREIGHT BILL | CARR |
| 11495006 | DEC264759A | WWAT |
| 11497865 | DEC-259114 | WWAT |
| 11498319 | DEC259154A | WWAT |
| 12503276 | DEC262166A | WWAT |
| 11505932 | DEC-262929 | WWAT |
| 11026858 | DEC-263118A | WWAT |
| 11525202 | DEC271361 | WWAT |
| 11527840 | DEC271594 | WWAT |
| 11530502 | 268060 | WWAT |

Report Number: REPB309
Requested By:
CONTROLLED ITEM RECEIPTS - DETAIL
WALGREENS
ZO9t + (LO) anads Jษ NISSnxvyaha

$\stackrel{\ddot{3}}{\stackrel{3}{4}}$


REPORT PERIOD : $\begin{array}{r}2 / 23 / 05 \\ \text { OTEM } \\ 2 / 27 / 06 \\ \text { DESCRIPTION }\end{array}$
REPORT PERIOD
ITEM
CATEGORY . .
VENDOR NAME : : QUALITST C


号量

DATE
RECEIVED
$11 / 21 / 05$
$11 / 22 / 05$
$12 / 01 / 05$
$12 / 09 / 05$
$12 / 16 / 05$
$12 / 21 / 05$
$2 / 10 / 06$
$2 / 16 / 06$
$2 / 24 / 06$
**** End of Report



$\begin{array}{ll} & \\ \text { Date．．．：} & 2 / 27 / 06 \\ \text { Time．．．：} & 13: 23: 26 \\ \text { Page．．．：} & 2\end{array}$

 $\begin{gathered}\text { PURCHASE } \\ \text { ORDER }\end{gathered}$
11455445
11458103
11460550
12462766
11465252
11467813
11470050
11475263
11472490
21477828
11480335
11483195
11485723
11488149
11490572
11492972
11495540
11498307
433701 WALGREENS
CONTROLLED ITEM RECEIPTS－DETAIL
$\stackrel{3}{8}$

anoot＋（EEV）OSL－S．LSE NIOODIA

|  |  |  | $\begin{aligned} & \stackrel{g}{8} \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} & \text { en } \\ & \stackrel{0}{0} \\ & \text { O } \end{aligned}$ |  | $\begin{aligned} & \ddot{0} \\ & \stackrel{0}{8} \\ & \frac{\tilde{4}}{} \end{aligned}$ | $\begin{aligned} & \text { g } \\ & \frac{8}{4} \\ & \text { K } \end{aligned}$ |  | $\begin{aligned} & \text { y } \\ & 0 \\ & \text { e } \end{aligned}$ | $\begin{aligned} & \text { ص. } \\ & \stackrel{\mathbb{Z}}{\mathbb{3}} \end{aligned}$ | $\begin{aligned} & n_{0}^{\prime} \\ & \frac{\underset{4}{6}}{} \end{aligned}$ | $\begin{aligned} & \text { gi } \\ & \stackrel{0}{u} \\ & \frac{\alpha}{4} \end{aligned}$ | $\begin{aligned} & 8 \\ & 8 \\ & 8 \\ & 8 \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 0 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} & \text { en } \\ & 8 \\ & \text { ex } \end{aligned}$ | $\begin{aligned} & \stackrel{9}{8} \\ & \stackrel{\alpha}{4} \\ & \hline \end{aligned}$ |  | $\begin{aligned} & 0 \\ & 8 \\ & 0 \\ & \text { d } \end{aligned}$ | $\begin{aligned} & \text { y } \\ & 8 \\ & 8 \\ & 4 \end{aligned}$ | $$ |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\ddot{B}$ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | － | － | $\stackrel{\circ}{\circ}$ | $\stackrel{\circ}{-}$ | － | － | － | $\stackrel{\circ}{\sim}$ | $\stackrel{8}{\circ}$ | N゙ | $\stackrel{\text {－}}{\stackrel{\text { ¢ }}{\sim}}$ | － | 吕 | $\stackrel{\square}{\sim}$ | 읐 | $\stackrel{\circ}{\square}$ | $\stackrel{\circ}{\square}$ | 。 | 8 | 8 |  |


 Report Number：REPB309
Requested By： aDI $\begin{array}{cc}\begin{array}{c}\text { DATE } \\ \text { APPROVED }\end{array} & \begin{array}{c}\text { ADJ } \\ \text { IND }\end{array} \\ \text { 8／02／05 } & \begin{array}{c}\text { CASE } \\ \text { PACK }\end{array} \\ \text { B／11／05 } & 60 \\ 8 / 18 / 05 & 60 \\ 8 / 25 / 05 & 60 \\ 8 / 26 / 05 & 60 \\ 9 / 06 / 05 & 60 \\ 9 / 12 / 05 & 60 \\ 9 / 29 / 05 & 60 \\ 9 / 30 / 05 & 60 \\ 10 / 07 / 05 & 60 \\ 10 / 11 / 05 & 60 \\ 10 / 18 / 05 & 60 \\ 10 / 25 / 05 & 60 \\ 10 / 27 / 05 & 60 \\ 11 / 04 / 05 & 60 \\ 12 / 26 / 05 & 60 \\ 12 / 22 / 05 & 60 \\ 11 / 28 / 05 & 60 \\ \text { B50 AIRPRT } & \text { DISTRIBUTION } \\ 12 / 02 / 05 & 60 \\ 12 / 13 / 05 & 60 \\ 12 / 16 / 05 & 60 \\ 12 / 23 / 05 & 60\end{array}$ REPORT PERIOD
ITEM
CATEGORY ．
VENDOR
VENDOR NAME
VEND SHP POINT
DEA Number． DATE
RECEIVED
B／01／05
B／10／05

[^3] 9／06／05 $9 / 12 / 05$
$9 / 28 / 05$ 9／29／05
$10 / 05 / 05$
$10 / 10 / 05$
$10 / 18 / 05$
$10 / 24 / 05$
$10 / 26 / 05$
$11 / 03 / 05$ 12／15／05


$\begin{array}{ll}\text { Date...: } & 2 / 27 / 06 \\ \text { Time...: } & 13: 23: 26 \\ \text { Page...: } & 3\end{array}$


Report Number: REPB309
Requested By :
WALGREENS
CONTROLLED ITEM RECEIPTS -
BNOOT + (gEy) OSL-5'L SE NIGOOTM
 8
8
8
8
$\stackrel{\ddot{4}}{8}$
$\stackrel{9}{4}$
CONTROLLED ITEM RECEIPTS - DETAIL
 $2 / 27 / 0$
SCRIPTS


 2/23/05
DE RN0209583

REPORT PERIOD
ITEM
CATEGORY
VENDOR NAME
DEA Number .
DATE
RECEIVED
$22 / 29 / 05$
RNO209583
$1 / 16 / 06$


| $m$ |
| :--- |
| 0 |
| 0 |
| 0 |
| 0 |
| 0 |
| 0 |
| 0 |
| 0 |
| 0 |

6
0
0
0
0
0
0
0
7
7
m
0
0
0
0
0
0
0
0
0
0
0

**** End of Report ****


| PURCHASE |
| :---: |
| ORDER |

11014277
11035510
11400839
11403565
11406207
11408885
11411675
11414463
11417013
11419800
11422729
11425447
11428149
11430667
11433178
11435866
11439446
11442063
11444718
11447198
11449793
11452582


$$
\begin{array}{cc}
\text { Date...: } & 2 / 27 / 06 \\
\text { Time...: } & 13: 23: 32 \\
\text { Page...: } & 1
\end{array}
$$




| Report Number: RepB309 Requested By.: AGALLAHERD |  |  |  |  | walgremes |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| REPORT PERIOD : 2/23/05 - 2/2 |  |  |  |  |  |  |  |  |  |
| ITEM | 6 | 684556 | descri | ON | VICODIN 5/500 | TPAB (ABB) +100 NPCITY: |  |  |  |
| CATEGORY | . . . ${ }^{\text {a }}$ | ARCOS D | ugs |  |  |  |  |  |  |
| VENDOR . . . . : 054294 |  |  |  |  |  |  |  |  |  |
| VENDOR NAME : CRNDL |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  | CITY: |  |  |  |
| $\underset{\text { RECEIVED }}{\text { DATE }}$ | $\begin{gathered} \text { DATE } \\ \text { APPROVED } \end{gathered}$ | ADJ | CASE | ORDERED ONLIES |  |  |  |  |  |
|  |  | D IND | PACK |  | onlies |  |  | category |  |
| 8/01/05 | 8/02/05 |  | 50 | 120 | 120 | arcos |  |  |  |
| 8/10/05 | 8/11/05 |  | 50 | 120 | 120 | arcos |  |  |  |
| 8/16/05 | 8/18/05 |  | 60 | 120 | 120 | arcos |  |  |  |
| 8/23/05 | 8/25/05 |  | 60 | 120 | 120 | arcos |  |  |  |
| 8/24/05 | 8/26/05 |  | 60 | 120 | 120 | ARCOS |  |  |  |
| 9/06/05 | 9/06/05 |  | 60 | 120 | 120 | ARCOS |  |  |  |
| 9/14/05 | 9/16/05 |  | 60 | 120 | 120 | arcos |  |  |  |
| 9/28/05 | 9/29/05 |  | 50 | 220 | 120 | arcos |  |  |  |
| 9/29/05 | 9/30/05 |  | 60 | 180 | 180 | arcos |  |  |  |
| 10/05/05 | 10/07/05 |  | 60 | 120 | 120 | ARCOS |  |  |  |
| 10/21/05 | 10/13/05 |  | 60 | 120 | 120 | arcos |  |  |  |
| 20/20/05 | 10/20/05 |  | 60 | 180 | 180 | arcos |  |  |  |
| 10/24/05 | 10/25/05 |  | 60 | 180 | 180 | arcos |  |  |  |
| 10/26/05 | 10/27/05 |  | 60 | 120 | 120 | ARCOS |  |  |  |
| 21/03/05 | 11/04/05 |  | 60 | 60 | 60 | arcos |  |  |  |
| 12/15/05 | 11/16/05 |  | 60 | 180 | 180 | arcos |  |  |  |
| 12/22/05 | 11/22/05 |  | 60 | 60 | 60 | arcos |  |  |  |
| $\begin{aligned} & 11 / 28 / 05 \\ & \text { RNO231427 } \\ & 12 / 02 / 05 \end{aligned}$ | 11/28/05 850 AIRPORT |  | 60 | VE 200 | 200 | arcos |  |  |  |
|  |  | distr | bution |  |  |  |  |  |  |
|  | - ${ }^{\text {d2/02/05 }}$ |  | 60 | - 120 | 120 | arcos |  |  |  |
| 12/13/05 | 12/13/05 |  | 60 | 180 | 180 | arcos |  |  |  |
| RN0209583 |  |  |  |  |  |  |  |  |  |
| 12/13/05 RN0209583 | 12/16/05 |  | 60 | 120 | 120 | Arcos |  |  |  |
| 12/21/05 | 22/23/05 |  | 60 | 300 | 300 | arcos |  |  |  |
| RNO209583 |  |  |  |  |  |  |  |  |  |

$\begin{array}{lc}\text { Date...: } & 2 / 27 / 06 \\ \text { Time...: } & 13: 233: 32 \\ \text { Page...: } & 3\end{array}$

$\underset{\substack{\text { M } \\ \multirow{3}{*}{\hline}\\ \hline}}{ }$




WALGREENS
VICODIN 5/500 TAB (ABB
: ス.l12

Facsimile Transmittal

| To: | Dwayne Pinon | Fax: | $847-315-4660$ |  |
| :--- | :--- | :--- | :--- | :--- |
| From: | Darlene Gallaher, Perrysburg DC | Date: | $4 / 15 / 09$ |  |
| Re: | 307 and 309 reports |  | Pages: | 5 (including cover sheet) |
| CC: | $\square$ For Revieww | $\square$ Please Comment | $\square$ Please Reply $\quad \square$ Please Recycle |  |

## Redacted - Attorney Client Privileged

Thank you,
Darlene Gallaher, Operations Admin Assistant
Perrysburg Distribution Center
419-662-4040

| Fax/Phone Number | Mode | Start | Time | Page | Result | Note |
| :--- | :---: | :--- | :--- | :--- | :--- | :---: |
| 918473154660 | S-Fine | $15: 12: 46 \mathrm{pm}$ | $1^{\prime} 19^{n}$ | 5 | $\# 0 \mathrm{~K}$ |  |

## Vrealgreent <br> Facsimile Transmittal



## Redacted - Attorney Client Privileged

Thank you,<br>Darlene Gallaher, Operations Admin Assistant<br>Perysbburg Distribution Conter<br>419-662-4040

解


|  |  |
| :---: | :---: |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |


| ATHORSTENS |  |
| :---: | :---: |
| ITEM.........: 645805 |  |
|  |  |
| VENDOR...... |  |
| VENDOR NAME . . |  |
| CATEGORY.....: ARCOS Dr |  |
|  |  |
| RECEIVED DESCRIPTION |  |
| 4/06/09 HYDROCOD-APAP$4 / 13 / 09$ HYDROCOD-APAP |  |
| END OF |  |

$\begin{array}{ll}\text { Date...: } & 4 / 15 / 09 \\ \text { Time...: } & 9: 58: 35 \\ \text { Page...: }\end{array}$ FREIGHT BILL
1173020AA
$1174328 A A A$


$\begin{array}{lc}\text { Date...: } & 4 / 15 / 09 \\ \text { Time...: } & 9: 58: 50 \\ \text { Page...: } & 1\end{array}$
FREIGHT BILL
4997013
5009791
5042023
PURCHASE
ORDER
11456949
11458257
11461093
$3 \times 30$
0
2
101
$m$
0
0
7
4
$\square$
Report Number: REPB309
Requested By.: ATHORSTENS

1 Itm rct rpt
ZIP: 45840
OH
CONTROL
ATEGORY
TL DRUG
Requested By. :
MERIDIA 10MG CAP
CARR
KEYI
KEYI
KEYI
CARR
KEYI
KEYI
KEYI
-

Darlene
Gallaher/LOG/Walgreens
04/15/2009 09:44 AM
To ramona.thorstenson@walgreens.com
cc steve.kneller@walgreens.com
bcc
Subject Re: Fw: DEA Perrysburg Visit March 2006

## $645805-4$

## Hi Mona,

## Redacted - Attorney Client Privileged

Thank you,
Darlene Gallaher
Operations Administrative Assistant
Perrysburg Distribution Center
Direct line: 419-662-4040
Fax: 419-662-2173
--.- Forwarded by Darlene Gallaher/LOG/Nalgreens on 04/15/2009 09:41 AM --
Steve Kneller/LOGNWalgreens

04/15/2009 09:40 AM
${ }^{\text {To }}$ Dariene Gallaher/LOG/Walgreens@Walgreens
cc
Subject Re: Fw: DEA Perrysburg Visil March 2006Link

# Redacted - Attorney Client Privileged 

Steve

## Thelgreaks



## Darlene GallaherlLOG/Walgreens

04/15/2009 09:35 AM

> To steve.kneller@walgreens.com
cc
Subject Re: Fw: DEA Perrysburg Visit March 2006

# Redacted - Attorney Client Privileged 

Thank you,
Darlene Gallaher
Operations Administrative Assistant
Perrysburg Distribution Center
Direct line: 419-662-4040
Fax: 419-662-2173
--.-Forwarded by Dartene Gallaher/LOG/Walgreens on 04/15/2009 09:34 AM --
Dwayne Pinon/Corp/Walgreens
To Dariene Gallaher/LOG/Walgreens@Walgreens
$c_{\text {justin.joseph@walgreens.com }}$
04/15/2009 09:33 AM
Subject Re: Fw: DEA Perrysburg Visit March 2006Link
nariene

# Redacted - Attorney Client Privileged 

Dwayne A. Pinon, RPh, Senior Attomey
Corporate \& Regulatory Law
104 Wilmot Road, MS 1447
Deerfield, IL 60015
(847) 315-4452
(847) 315-4660 (fax)

This message and any attachments are confidential attorney work product and may also be protected by the attorney-cient privilege. If you have received this message and are not the intended recipient, please contact the sender at dwayne.pinon@walgreens.com.

## Darlene Gallaher/LOG/Walgreens

04/15/2009 08:27 AM

To Dwayne Pinon/Corp/Walgreens@Walgreens
${ }^{c c}{ }_{\text {justin.joseph@walgreens.com }}$
Subject Fw: DEA Perrysburg Visit March 2006

## Redacted - Attorney Client Privileged

Thank you!
Darlene Gallaher
Operations Administrative Assistant
Perrysburg Distribution Center
Direct line: 419-662-4040
Fax: 419-662-2173
---. Forwarded by Dariene Gallaher/LOG/Nalgreens on 04/15/2009 09:26 AM .....
Dariene Gallaher/LOG/Walgreens

04/03/2009 06:01 AM
To Dwayne Pinon/Corp/Walgreens
$c_{\text {justin.joseph@walgreens.com }}$
Subject Fw: DEA Perrysburg Visit March 2006

## Redacted - Attorney Client Privileged

Thank you,
Darlene Gallaher
Operations Admin Assistant
Perrysburg Distribution Center
419-662-4040
_-. Forwarded by Steve Kneller/LOGWaigreens on 04/02/2009 05:40 PM --

# Redacted - Attorney Client Privileged 

Thank You,
James VanOverbake
Internal Audit - Walgreens
1417 Lake Cook Road MS\#L164
Deerfield, IL 60015-5223
P: (847) 964-4130
F: (847) 964-4966
--.- Forwarded by James VanOverbake/Corp/Walgreens on 03/11/2009 08:23 AM .--....
Steve Kneller/LOG/Walgreens

03/10/2009 01:58 PM
To dan.coughlin@walgreens.com, James VanOverbake/Corp/Walgreens@Walgreens
${ }^{c c}$ bob.rogan@walgreens.com
Subject DEA Perrysburg Visit March 2006

## Redacted - Attorney Client Privileged

## Telalgneens


[^0]:    Report Number: REPB309
    Requested By.: AGALLAHERD

[^1]:    WALGREENS
    CONTROLLED ITEM RECEIPTS－detail
    8 ：XLIS
    
     xanax img tab
     $2 / 23 / 05-2 / 27 / 06$
    DESCRIPTION
    

    PFIZER＂C＂
    1025 SANDHILL ROAD
    II1778240
    思总
    6
    30
    $30_{4}^{2}$
    $\stackrel{\oplus}{\square}$
    $\stackrel{\infty}{*}$ $\stackrel{\infty}{\sim}$ $\stackrel{\infty}{*}$ $\stackrel{\infty}{\infty}$ $\stackrel{\infty}{*} \stackrel{\infty}{*}$ $\stackrel{\infty}{\square}$ $\stackrel{\infty}{*}$ ${ }^{\infty}$ $\stackrel{\infty}{*}$ $\stackrel{\infty}{*} \stackrel{\infty}{\sigma}$ $\underset{\sim}{\infty}$ $*$ ${ }^{\infty}$ $\stackrel{\infty}{\infty}$ ${ }_{*}^{\infty}{ }_{\sim}^{\infty}$ $\stackrel{\infty}{*}$

    Report Number：REPB309
    Requested By ：AGALLAHERD
    REPORT PERIOD
    TTEM
    CAEGORX $\quad . \quad$
    VENDR
    VENOR NAME
    VEND SHIP POINT
    DEA Number ．．
     $\stackrel{n}{\circ}$ $\frac{\stackrel{0}{\circ}}{\stackrel{3}{\circ}}$
    
     $\stackrel{\text { n }}{\stackrel{2}{-}}$ $\frac{\stackrel{n}{9}}{\stackrel{3}{\infty}}$ $\stackrel{\text { n }}{\stackrel{\circ}{\circ}}$
    
     $\stackrel{8}{\stackrel{\circ}{8}}$ nn
    9
    9
    9 10／14／05 $\stackrel{n}{\stackrel{n}{9}}$ 10／25／05

     \begin{tabular}{l}
    n <br>
    - <br>
    - <br>
    - <br>
    \hline

    $\stackrel{\text { n }}{\stackrel{4}{\circ}}$ $\stackrel{n}{\stackrel{n}{0}} \stackrel{\stackrel{8}{8}}{\stackrel{3}{9}} \stackrel{0}{9}$ 

    DATE <br>
    RECEIVED <br>
    7／25／05 <br>
    $8 / 03 / 05$ <br>
    $8 / 04 / 05$ <br>
    $8 / 16 / 05$ <br>
    8／17／05 <br>
    $8 / 22 / 05$ <br>
    $8 / 30 / 05$ <br>
    $9 / 09 / 05$ <br>
    $9 / 16 / 05$ <br>
    $9 / 17 / 05$ <br>
    9／28／05 <br>
    9／29／05 <br>
    $10 / 06 / 05$ <br>
    $10 / 14 / 05$ <br>
    $10 / 17 / 05$ <br>
    \hline $10 / 24 / 05$ <br>
    \hline $11 / 02 / 05$ <br>
    \hline $11 / 08 / 05$ <br>
    \hline $11 / 10 / 05$ <br>
    \hline $11 / 21 / 05$ <br>
    $11 / 25 / 05$ <br>
    \hline $12 / 05 / 05$
    \end{tabular}

[^2]:    |  | 8 |
    | :---: | :---: | RNO209583

    ，
    REPORT PERIOD ：$\quad 2 / 23 / 05 \stackrel{2 / 27 / 06}{\text { 2／2 }}$
    是号 Drugs
    05429
    CRNDI
    RNO 20
     ＊＊＊＊End of Report
    CATEGORY
    VENDOR
    VENDOR NAME
    VEND SHIP POINT
    054294
    CRND＂C＂
    

    DATE
    RECEIVEd
    
    
    －
    

[^3]:    8／16／05 8／24／05

